Pre-order Enquiry
Request Free Sample
Global Chemotherapy-induced Nausea and Vomiting Drugs Market Report, History and Forecast 2014-2025, Breakdown Data by Manufacturers, Key Regions, Types and Application
SKU ID : QYR-14050234 | Publishing Date : 03-Apr-2019 | No. of pages : 134
Summary
Chemotherapy induced nausea and vomiting (CINV) drugs refer to medication or treatment that is offered to cancer patients who experience nausea and vomiting due to chemotherapy.
The classification of Chemotherapy Induced Nausea and Vomiting (CINV) Drugs includes 5-HT3 Inhibitors, NK1 Inhibitors and others. The proportion of 5-HT3 Inhibitors in 2017 is about 62%, and the proportion of NK1 Inhibitors in 2017 is about 33%.
Chemotherapy Induced Nausea and Vomiting (CINV) Drugs are application for Highly Emetogenic Chemotherapy, Moderately Emetogenic Chemotherapy, Low Emetogenic Chemotherapy and others. The most of Chemotherapy Induced Nausea and Vomiting (CINV) Drugs is used for Moderately Emetogenic Chemotherapy, and the market share of that is about 52 % in 2017.
North America is the largest consumption place, with a consumption market share nearly 51% in 2017; Europe is the second largest consumption place with the consumption market share of 21% in 2017.
Market competition is not intense. Merck, Eisai, Mundipharma, Qilu Pharma, Teva, Novartis etc. are the leaders of the industry with the market share are about 66% in 2017.
The global Chemotherapy-induced Nausea and Vomiting Drugs market was 1740 million US$ in 2018 and is expected to 2460 million US$ by the end of 2025, growing at a CAGR of 4.4% between 2019 and 2025.
This report studies the Chemotherapy-induced Nausea and Vomiting Drugs market size (value and volume) by players, regions, product types and end industries, history data 2014-2018 and forecast data 2019-2025; This report also studies the global market competition landscape, market drivers and trends, opportunities and challenges, risks and entry barriers, sales channels, distributors and Porter's Five Forces Analysis.
Geographically, this report is segmented into several key regions, with sales, revenue, market share and growth Rate of Chemotherapy-induced Nausea and Vomiting Drugs in these regions, from 2014 to 2025, covering
North America (United States, Canada and Mexico)
Europe (Germany, UK, France, Italy, Russia and Turkey etc.)
Asia-Pacific (China, Japan, Korea, India, Australia, Indonesia, Thailand, Philippines, Malaysia and Vietnam)
South America (Brazil etc.)
Middle East and Africa (Egypt and GCC Countries)
The various contributors involved in the value chain of the product include manufacturers, suppliers, distributors, intermediaries, and customers. The key manufacturers in this market include
Merck
Eisai
Mundipharma
Qilu Pharma
Teva
Novartis
Heron Therapeutics
Roche
Mylan
Tesaro
By the product type, the market is primarily split into
5-HT3 Inhibitors
NK1 Inhibitors
Other
By the end users/application, this report covers the following segments
Highly Emetogenic Chemotherapy
Moderately Emetogenic Chemotherapy
Low Emetogenic Chemotherapy
Other
We can also provide the customized separate regional or country-level reports, for the following regions:
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Rest of Asia-Pacific
Europe
Germany
France
UK
Italy
Spain
Russia
Rest of Europe
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa
Rest of Middle East & Africa
The study objectives of this report are:
To study and analyze the global Chemotherapy-induced Nausea and Vomiting Drugs market size (value & volume) by company, key regions/countries, products and application, history data from 2014 to 2018, and forecast to 2025.
To understand the structure of Chemotherapy-induced Nausea and Vomiting Drugs market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Chemotherapy-induced Nausea and Vomiting Drugs manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Chemotherapy-induced Nausea and Vomiting Drugs with respect to individual growth trends, future prospects, and their contribution to the total market.
To project the value and volume of Chemotherapy-induced Nausea and Vomiting Drugs submarkets, with respect to key regions (along with their respective key countries).
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.
In this study, the years considered to estimate the market size of Chemotherapy-induced Nausea and Vomiting Drugs are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
This report includes the estimation of market size for value (million USD) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Chemotherapy-induced Nausea and Vomiting Drugs market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
Key Stakeholders
Raw material suppliers
Distributors/traders/wholesalers/suppliers
Regulatory bodies, including government agencies and NGO
Commercial research & development (R&D) institutions
Importers and exporters
Government organizations, research organizations, and consulting firms
Trade associations and industry bodies
End-use industries
Available Customizations
With the given market data, offers customizations according to the company's specific needs. The following customization options are available for the report:
Further breakdown of Chemotherapy-induced Nausea and Vomiting Drugs market on basis of the key contributing countries.
Detailed analysis and profiling of additional market players.
Chemotherapy induced nausea and vomiting (CINV) drugs refer to medication or treatment that is offered to cancer patients who experience nausea and vomiting due to chemotherapy.
The classification of Chemotherapy Induced Nausea and Vomiting (CINV) Drugs includes 5-HT3 Inhibitors, NK1 Inhibitors and others. The proportion of 5-HT3 Inhibitors in 2017 is about 62%, and the proportion of NK1 Inhibitors in 2017 is about 33%.
Chemotherapy Induced Nausea and Vomiting (CINV) Drugs are application for Highly Emetogenic Chemotherapy, Moderately Emetogenic Chemotherapy, Low Emetogenic Chemotherapy and others. The most of Chemotherapy Induced Nausea and Vomiting (CINV) Drugs is used for Moderately Emetogenic Chemotherapy, and the market share of that is about 52 % in 2017.
North America is the largest consumption place, with a consumption market share nearly 51% in 2017; Europe is the second largest consumption place with the consumption market share of 21% in 2017.
Market competition is not intense. Merck, Eisai, Mundipharma, Qilu Pharma, Teva, Novartis etc. are the leaders of the industry with the market share are about 66% in 2017.
The global Chemotherapy-induced Nausea and Vomiting Drugs market was 1740 million US$ in 2018 and is expected to 2460 million US$ by the end of 2025, growing at a CAGR of 4.4% between 2019 and 2025.
This report studies the Chemotherapy-induced Nausea and Vomiting Drugs market size (value and volume) by players, regions, product types and end industries, history data 2014-2018 and forecast data 2019-2025; This report also studies the global market competition landscape, market drivers and trends, opportunities and challenges, risks and entry barriers, sales channels, distributors and Porter's Five Forces Analysis.
Geographically, this report is segmented into several key regions, with sales, revenue, market share and growth Rate of Chemotherapy-induced Nausea and Vomiting Drugs in these regions, from 2014 to 2025, covering
North America (United States, Canada and Mexico)
Europe (Germany, UK, France, Italy, Russia and Turkey etc.)
Asia-Pacific (China, Japan, Korea, India, Australia, Indonesia, Thailand, Philippines, Malaysia and Vietnam)
South America (Brazil etc.)
Middle East and Africa (Egypt and GCC Countries)
The various contributors involved in the value chain of the product include manufacturers, suppliers, distributors, intermediaries, and customers. The key manufacturers in this market include
Merck
Eisai
Mundipharma
Qilu Pharma
Teva
Novartis
Heron Therapeutics
Roche
Mylan
Tesaro
By the product type, the market is primarily split into
5-HT3 Inhibitors
NK1 Inhibitors
Other
By the end users/application, this report covers the following segments
Highly Emetogenic Chemotherapy
Moderately Emetogenic Chemotherapy
Low Emetogenic Chemotherapy
Other
We can also provide the customized separate regional or country-level reports, for the following regions:
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Rest of Asia-Pacific
Europe
Germany
France
UK
Italy
Spain
Russia
Rest of Europe
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa
Rest of Middle East & Africa
The study objectives of this report are:
To study and analyze the global Chemotherapy-induced Nausea and Vomiting Drugs market size (value & volume) by company, key regions/countries, products and application, history data from 2014 to 2018, and forecast to 2025.
To understand the structure of Chemotherapy-induced Nausea and Vomiting Drugs market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Chemotherapy-induced Nausea and Vomiting Drugs manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Chemotherapy-induced Nausea and Vomiting Drugs with respect to individual growth trends, future prospects, and their contribution to the total market.
To project the value and volume of Chemotherapy-induced Nausea and Vomiting Drugs submarkets, with respect to key regions (along with their respective key countries).
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.
In this study, the years considered to estimate the market size of Chemotherapy-induced Nausea and Vomiting Drugs are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
This report includes the estimation of market size for value (million USD) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Chemotherapy-induced Nausea and Vomiting Drugs market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
Key Stakeholders
Raw material suppliers
Distributors/traders/wholesalers/suppliers
Regulatory bodies, including government agencies and NGO
Commercial research & development (R&D) institutions
Importers and exporters
Government organizations, research organizations, and consulting firms
Trade associations and industry bodies
End-use industries
Available Customizations
With the given market data, offers customizations according to the company's specific needs. The following customization options are available for the report:
Further breakdown of Chemotherapy-induced Nausea and Vomiting Drugs market on basis of the key contributing countries.
Detailed analysis and profiling of additional market players.
Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
Request Sample
Request Discount
